News
Time is Blood! Impact of Diagnostic Delays on Prognosis of Patients with Acquired Hemophilia A
The famous slogan of neurologists in connection with strokes – 'Time is brain!' – can be modified to 'Time is blood!' for the issue of acquired hemophilia A (AHA). The factor of time plays a crucial role in the prognosis of patients with AHA – delayed diagnosis is associated with longer administration of hemostatic treatment, higher risk of relapses, and mortality.
Treatment of Depression with Persistent Severe Insomnia − Interactive Case Study
A 39-year-old patient comes to the psychiatric office due to depressive symptoms with anxiety and…
Urgent Administration of Romiplostim in Life-Threatening Bleeding Associated with ITP
Recommendations for the care of acute, especially major bleeding in individuals with severe immune…
Consensus on the Administration of TPO-RA as Second-Line Therapy in ITP
What is the role of thrombopoietin receptor agonists (TPO-RA) in the second line treatment of…
Brentuximab vedotin in combination with lenalidomide and rituximab in R/R DLBCL – results from the open part of the ECHELON-3 study
The aim of the open run-in phase of the randomized placebo-controlled phase III ECHELON-3 study,…
6-year data from the ECHELON-1 study: How does combining brentuximab vedotin with chemotherapy affect overall survival of previously untreated cHL patients?
At this year's annual congress of the European Hematology Association (EHA), results from the…
How to Save a Leg from Amputation?
Feared complications in diabetics include defects in typical locations on the lower limbs. Their…
Prophylaxis EHL products FVIII bring improvements in clinical and pharmacokinetic results
A freshly published real-world clinical practice study from Spain highlights the experience of…
Benefit of Adding Empagliflozin to Standard Therapy in Heart Failure with Reduced Ejection Fraction
The use of empagliflozin led to a reduction in the risk of hospitalization for heart failure or…
Sequential administration of immunochemotherapy and venetoclax after failure of BCR inhibitor treatment – interactive video case study
The treatment of chronic lymphocytic leukemia (CLL) is evolving. What was impossible years ago is…